X

Trial Profile

Randomized phase II study of docetaxel + bevacizumab or pemetrexed + bevacizumab for elderly non-squamous non-small-cell lung cancer. (TORG1323)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Docetaxel; Pemetrexed
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

26 Sep 2018 Primary endpoint has not been met. (Progression-free survival)
26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
03 Mar 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com